Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Novel Antimicrobials for Killing Anthrax

by Global Biodefense Staff
June 7, 2012

The CDC’s Division of High-Consequence Pathogens and Pathology (DHCPP) Bacterial and Special Pathogens Branch this week announced its intent to issue a purchase order to the University of Michigan Life Sciences Institute for the production of novel antimicrobials for specific killing of Bacillus anthracis.

Despite the problem of bacteria becoming increasingly resistant to the current arsenal of therapeutic agents, few novel classes of antimicrobials have been discovered.  In addition to naturally acquired resistance, there is increasing concern that engineered, multi-drug resistant (MDR) strains could be used in a bioterrorism event.  According to the CDC, such an occurrence could greatly limit or eliminate their ability to effectively treat diseases such as anthrax, where early administration of appropriate antimicrobials is critical for care and a positive patient outcome.

One approach in recent years has been to use anti-sense oligonucleotides (oligos) to target specific mRNA to inhibit bacterial growth. Although the anti-sense approach has been used since the 1970s, several developments have led to more recent success. First was the development of morpholino oligos, which are resistant to ribonucleases, and thus more stable. Second was the addition of membrane-penetrating peptides to morpholino oligos in order to increase uptake and effectively kill bacteria.

The planned effort involves using morpholino oligos linked to Bacillus anthracis siderophores to treat anthrax. The siderophores bind iron and the iron-siderophore complex is then transported across the cell envelope into the cell. The siderophore would act as a “Trojan horse” and lead to the active uptake of the drug, and approach that has been used successfully with traditional antibiotics.

Work to generate a new class of antimicrobial agents will focus on generating a modified form of the virulence factor petrobactin that is covalently modified with an anti-sense morpholino oligonucleotide. The process requires the development of a method to conjugate a morpholino-oligonucleotide to the siderophore. This molecule would be recognized by receptors on the cell surface of the bacteria, and internalized where the covalently linked antisense oligonucleotide would bind to its complimentary strand of RNA blocking translation of genes necessary for growth.

Such a process could be applied as a means of killing other pathogenic bacteria and used as a therapeutic in the case of organisms with resistance to currently used antibiotics.

The contract effort is managed under Solicitation Number: 00HCVLEG-2012-43251.

Tags: AnthraxAntimicrobialsBioterrorism

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC